TY - JOUR
T1 - The use of cell-sheet technique eliminates arrhythmogenicity of skeletal myoblast-based therapy to the heart with enhanced therapeutic effects
AU - Narita, Takuya
AU - Shintani, Yasunori
AU - Ikebe, Chiho
AU - Kaneko, Masahiro
AU - Harada, Narumi
AU - Tshuma, Nomathamsanqa
AU - Takahashi, Kunihiko
AU - Campbell, Niall G.
AU - Coppen, Steven R.
AU - Yashiro, Kenta
AU - Sawa, Yoshiki
AU - Suzuki, Ken
N1 - Funding Information:
Grant support: this work was supported by the UK National Institute of Health Research (New and Emerging Applications of Technology Programme ( NEAT L018 ) and Cardiovascular Biomedical Research Unit Award ), and the Barts and The London Charity ( ETHG1B8R ).
PY - 2013/9/20
Y1 - 2013/9/20
N2 - Background: Clinical application of skeletal myoblast transplantation has been curtailed due to arrhythmogenicity and inconsistent therapeutic benefits observed in previous studies. However, these issues may be solved by the use of a new cell-delivery mode. It is now possible to generate "cell-sheets" using temperature-responsive dishes without artificial scaffolds. This study aimed to validate the safety and efficacy of epicardial placement of myoblast-sheets (myoblast-sheet therapy) in treating heart failure. Methods and results: After coronary artery ligation in rats, the same numbers of syngeneic myoblasts were transplanted by intramyocardial injection or cell-sheet placement. Continuous radio-telemetry monitoring detected increased ventricular arrhythmias, including ventricular tachycardia, after intramyocardial injection compared to the sham-control, while these were abolished in myoblast-sheet therapy. This effect was conjunct with avoidance of islet-like cell-cluster formation that disrupts electrical conduction, and with prevention of increased arrhythmogenic substrates due to exaggerated inflammation. Persistent ectopic donor cells were found in the lung only after intramyocardial injection, strengthening the improved safety of myoblast-sheet therapy. In addition, myoblast-sheet therapy enhanced cardiac function, corresponding to a 9.2-fold increase in donor cell survival, compared to intramyocardial injection. Both methods achieved reduced infarct size, decreased fibrosis, attenuated cardiomyocyte hypertrophy, and increased neovascular formation, in association with myocardial upregulation of a group of relevant molecules. The pattern of these beneficial changes was similar between two methods, but the degree was more substantial after myoblast-sheet therapy. Conclusion: The cell-sheet technique enhanced safety and therapeutic efficacy of myoblast-based therapy, compared to the current method, thereby paving the way for clinical application.
AB - Background: Clinical application of skeletal myoblast transplantation has been curtailed due to arrhythmogenicity and inconsistent therapeutic benefits observed in previous studies. However, these issues may be solved by the use of a new cell-delivery mode. It is now possible to generate "cell-sheets" using temperature-responsive dishes without artificial scaffolds. This study aimed to validate the safety and efficacy of epicardial placement of myoblast-sheets (myoblast-sheet therapy) in treating heart failure. Methods and results: After coronary artery ligation in rats, the same numbers of syngeneic myoblasts were transplanted by intramyocardial injection or cell-sheet placement. Continuous radio-telemetry monitoring detected increased ventricular arrhythmias, including ventricular tachycardia, after intramyocardial injection compared to the sham-control, while these were abolished in myoblast-sheet therapy. This effect was conjunct with avoidance of islet-like cell-cluster formation that disrupts electrical conduction, and with prevention of increased arrhythmogenic substrates due to exaggerated inflammation. Persistent ectopic donor cells were found in the lung only after intramyocardial injection, strengthening the improved safety of myoblast-sheet therapy. In addition, myoblast-sheet therapy enhanced cardiac function, corresponding to a 9.2-fold increase in donor cell survival, compared to intramyocardial injection. Both methods achieved reduced infarct size, decreased fibrosis, attenuated cardiomyocyte hypertrophy, and increased neovascular formation, in association with myocardial upregulation of a group of relevant molecules. The pattern of these beneficial changes was similar between two methods, but the degree was more substantial after myoblast-sheet therapy. Conclusion: The cell-sheet technique enhanced safety and therapeutic efficacy of myoblast-based therapy, compared to the current method, thereby paving the way for clinical application.
KW - Bioengineering technology
KW - Cell-based therapy
KW - Cell-sheet technique
KW - Heart failure
KW - Intramyocardial injection
KW - Ventricular arrhythmia
UR - http://www.scopus.com/inward/record.url?scp=84883828955&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84883828955&partnerID=8YFLogxK
U2 - 10.1016/j.ijcard.2012.09.081
DO - 10.1016/j.ijcard.2012.09.081
M3 - Article
C2 - 23046598
AN - SCOPUS:84883828955
SN - 0167-5273
VL - 168
SP - 261
EP - 269
JO - International Journal of Cardiology
JF - International Journal of Cardiology
IS - 1
ER -